Ausdal Financial Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Ausdal Financial Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$413K	Sell	926 -12	-1%	-$5.6K	0.02%	655
2025 Q4	$425K	Sell	938 -575	-38%	-$248K	0.02%	613
2025 Q3	$593K	Buy	1,513 +743	+96%	+$311K	0.03%	501
2025 Q2	$343K	Sell	770 -10	-1%	-$4.61K	0.02%	517
2025 Q1	$378K	Buy	780 +23	+3%	+$10.7K	0.03%	447
2024 Q4	$305K	Buy	757 +43	+6%	+$19.9K	0.03%	445
2024 Q3	$332K	Buy	714 +30	+4%	+$14.4K	0.03%	389
2024 Q2	$321K	Buy	684 +97	+17%	+$42.1K	0.03%	369
2024 Q1	$245K	Buy	587 +94	+19%	+$39.7K	0.03%	407
2023 Q4	$201K	Buy	+493	New	+$182K	0.02%	425
2022 Q1	–	Sell	-14,981	Closed	-$3.29M	–	530
2021 Q4	$3.29M	Buy	+14,981	New	+$2.91M	0.44%	62
2016 Q1	–	Sell	-31	Closed	-$4K	–	1011
2015 Q4	$4K	Buy	+31	New	+$3.74K	﹤0.01%	1134

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ausdal Financial Partners's VRTX Position: Q1 2026 in Review

Ausdal Financial Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 1.3% in Q1 2026, selling an estimated $5.6K and leaving 926 shares worth $413K. The position accounts for 0.02% of the portfolio, ranked #655.

Ausdal Financial Partners first reported a position in VRTX in Q4 2015 and has held it in 12 quarters since. The position peaked at $3.29M in Q4 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Ausdal Financial Partners held 926 shares of Vertex Pharmaceuticals worth $413K as of Q1 2026.
Ausdal Financial Partners sold 12 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.6K.
Vertex Pharmaceuticals made up 0.02% of Ausdal Financial Partners's portfolio in Q1 2026, its #655 holding.
Ausdal Financial Partners first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 12 quarters since.
Ausdal Financial Partners's Vertex Pharmaceuticals position peaked at $3.29M in Q4 2021.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Ausdal Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.